You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 18, 2025

CLINICAL TRIALS PROFILE FOR ADRUCIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Adrucil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed National Cancer Institute (NCI) Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed M.D. Anderson Cancer Center Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002525 ↗ Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed Terminated American College of Surgeons Phase 3 1993-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗ Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed Terminated Cancer and Leukemia Group B Phase 3 1993-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗ Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed Terminated National Cancer Institute (NCI) Phase 3 1993-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
NCT00002525 ↗ Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed Terminated NSABP Foundation Inc Phase 3 1993-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more effective with or without chemotherapy for colon cancer. PURPOSE: Randomized phase III trial to evaluate whether perioperative 5-Fluorouracil (5-FU) chemotherapy after curative resection could improve overall survival and disease-free survival in patients with Duke's B3 or C colon cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Adrucil

Condition Name

Condition Name for Adrucil
Intervention Trials
Breast Cancer 8
Pancreatic Cancer 6
Colorectal Cancer 6
Metastatic Pancreatic Adenocarcinoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Adrucil
Intervention Trials
Adenocarcinoma 19
Pancreatic Neoplasms 15
Colorectal Neoplasms 14
Carcinoma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Adrucil

Trials by Country

Trials by Country for Adrucil
Location Trials
United States 341
Spain 29
Japan 18
Australia 16
Canada 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Adrucil
Location Trials
Texas 34
California 20
Michigan 14
Illinois 14
Ohio 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Adrucil

Clinical Trial Phase

Clinical Trial Phase for Adrucil
Clinical Trial Phase Trials
Phase 3 8
Phase 2/Phase 3 3
Phase 2 41
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Adrucil
Clinical Trial Phase Trials
Completed 37
Recruiting 13
Terminated 12
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Adrucil

Sponsor Name

Sponsor Name for Adrucil
Sponsor Trials
National Cancer Institute (NCI) 30
M.D. Anderson Cancer Center 25
Genentech, Inc. 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Adrucil
Sponsor Trials
Other 76
Industry 52
NIH 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Adrucil (5-Fluorouracil): Clinical Trials, Market Analysis, and Projections

Introduction to Adrucil (5-Fluorouracil)

Adrucil, commonly known as 5-fluorouracil (5-FU), is a chemotherapeutic agent used to treat various types of cancer, including colon, esophageal, stomach, pancreatic, breast, and cervical cancers. Here, we will delve into the current clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Recent Developments

Ongoing and Completed Trials

Several clinical trials have been conducted or are ongoing to evaluate the efficacy and safety of 5-fluorouracil in different cancer types. For instance, the NIFTY trial, a randomized, multicenter, open-label, phase 2b clinical trial, investigated the addition of liposomal irinotecan to fluorouracil and leucovorin for patients with advanced biliary tract cancer (BTC). The trial showed significant improvement in progression-free survival (PFS) with the combination therapy compared to fluorouracil and leucovorin alone[4].

Combination Therapies

5-Fluorouracil is often used in combination with other drugs to enhance its therapeutic effects. For example, the combination of 5-FU with leucovorin and liposomal irinotecan has shown promising results in treating advanced BTC. Such combination therapies are a focus area in current clinical trials to optimize treatment outcomes[4].

Market Analysis

Market Size and Growth

The global 5-fluorouracil market is expected to register a significant compound annual growth rate (CAGR) by 2031. The market size in 2023 was valued at several million dollars and is projected to increase substantially over the forecast period. This growth is driven by the increasing prevalence of chronic diseases and cancer, along with rising demand for cell therapies and government initiatives to enhance healthcare facilities[2][5].

Regional Market Insights

The 5-fluorouracil market is segmented into several regions, including North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The APAC region is expected to exhibit the highest growth rate during the forecast period due to growing awareness, increasing investments in R&D, and the competitive pricing of 5-FU in this region[2][5].

Competitive Landscape

The global 5-fluorouracil market is highly competitive, with key players such as VHB Lifesciences Inc., Cadila Pharmaceuticals Ltd., Celon Labs, Neon Laboratories Ltd, Samarth Pharma Pvt. Ltd., and Alkem Laboratories Ltd. These companies are focusing on developing their technological expertise, product line extensions, and innovations to strengthen their market presence[5].

Market Dynamics

Drivers

  • Increasing Prevalence of Cancer: The rising incidence of various types of cancer globally is a major driver for the 5-fluorouracil market[2][5].
  • Government Initiatives: Government efforts to improve healthcare facilities and increase research funding are fueling the market growth[2].
  • Demand for Cell Therapies: The growing demand for advanced cell therapies in cancer treatment is another significant driver[2].

Restraints

  • Side Effects and Toxicity: 5-Fluorouracil is associated with several side effects and toxicity issues, which can limit its adoption in some cases[4].
  • Competition from Alternative Treatments: The emergence of new cancer treatments and therapies can pose a competitive challenge to 5-FU[5].

End-Use Insights

Treatment Settings

The hospitals segment captures a significant revenue share in the 5-fluorouracil market. Factors such as treatment accessibility, high penetration of surgery, and increasing photodynamic therapy procedures performed in hospitals support this segment's growth. Physician-assisted therapies like cryotherapy, photodynamic therapy (PDT), and laser therapy also contribute to the segment's expansion[3].

Product Insights

Efficacy and Adoption

5-Fluorouracil remains a leading segment in the treatment of actinic keratosis, with a high efficacy rate of up to 74% and significant therapeutic results. Its reliability and lower chances of non-response make it a preferred choice for treating various skin conditions and cancers[3].

Future Projections

Market Forecast

The global 5-fluorouracil market is expected to continue its steady growth through 2031. The market size is projected to increase from its current value to several million dollars by the end of the forecast period, driven by the factors mentioned above[2][5].

Emerging Trends

  • Precision Medicine: There is a growing focus on precision medicine approaches, which could further enhance the efficacy of 5-fluorouracil by tailoring treatments to individual patient profiles[1].
  • Combination Therapies: Continued research into combination therapies involving 5-FU is expected to yield more effective treatment options for various cancers[4].

Key Takeaways

  • Clinical Trials: Ongoing and completed trials, such as the NIFTY trial, highlight the potential of 5-fluorouracil in combination therapies.
  • Market Growth: The global 5-fluorouracil market is expected to grow significantly, driven by increasing cancer prevalence and government initiatives.
  • Regional Insights: The Asia-Pacific region is anticipated to exhibit the highest growth rate due to competitive pricing and growing awareness.
  • Competitive Landscape: The market is highly competitive, with key players focusing on technological advancements and product innovations.
  • End-Use: Hospitals remain a major segment due to treatment accessibility and increasing use of physician-assisted therapies.

FAQs

What is 5-fluorouracil used for?

5-Fluorouracil (Adrucil) is used to treat various types of cancer, including colon, esophageal, stomach, pancreatic, breast, and cervical cancers.

What are the key drivers of the 5-fluorouracil market?

The key drivers include the increasing prevalence of cancer, government initiatives to enhance healthcare facilities, and the growing demand for cell therapies.

Which region is expected to exhibit the highest growth rate in the 5-fluorouracil market?

The Asia-Pacific region is expected to exhibit the highest growth rate due to competitive pricing, growing awareness, and increasing investments in R&D.

What are the common side effects of 5-fluorouracil?

5-Fluorouracil is associated with several side effects, including nausea, vomiting, diarrhea, and toxicity issues.

What is the current market size of 5-fluorouracil, and what is its projected growth?

The current market size is valued at several million dollars, and it is projected to increase substantially by 2031, driven by various market dynamics.

Sources

  1. AstraZeneca, "Clinical trials appendix H1 2022 results update," [PDF].
  2. The Insight Partners, "5-Fluorouracil Market Key Findings by 2031."
  3. BioSpace, "U.S. Actinic Keratosis Treatment Market Size Industry Analysis 2033."
  4. JAMA Oncology, "Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Advanced Biliary Tract Cancer."
  5. Reports and Data, "Fluorouracil Market Size, Share | Industry Report, 2016-2027."
Last updated: 2025-01-02

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.